Late stage rare disease therapies fail patients most often when the science succeeds but the pathway to development and commercialization breaks. At the 2026 Global BioInnovation Forum conversation, Craig Martin, Founder and CEO of Orphan Therapeutics Accelerator, and David Barrett, CEO of the American Society of Gene and Cell Therapy, join Nicole Grubner, Partner at FINN Partners, to explain a newly announced collaboration designed to unlock hidden value in shelved cell and gene therapy assets through a clearinghouse and a new kind of marketplace. The model matters because continuity protects both the integrity of active trials and the urgency of families waiting for treatments that already show promise.